Software Solution for Healthcare Provider - Medical / Health Care - Clinical Services
Automated MRI analyses that may help inform earlier, more accurate viewsof CNS disease, such as Alzheimer’s, Parkinson’s and multiple sclerosis. For healthcare providers on the frontlines of diagnosing and treating central nervous system disease, and for your patients, Qynapse brings groundbreaking peace of mind by providing results you can trust through its flagship solution, QyScore.
Details
Alone, we stay exactly where we are. Together, we can move forward into the future of CNS disease diagnosis and treatment. Our FDA-Cleared and CE-Marked platform, QyScore®, in use in the US and EU and expanding soon into new global markets, is simple to access, easy to use, and integrates seamlessly with your existing clinical workflows in order to inform your clinical decisions.
Powered by robust technology, QyScore® provides objective measures that have the potential to improve the accuracy of your diagnosis, evaluate therapeutic impact and more precisely measure disease progression. With Qynapse, you and your patients will see the entire picture, clearly and quickly. This assists you, your patients and their loved ones to focus on treatment plans that may improve outcomes and quality of life.
For Radiology and Neurology:
QyScore® offers precise, automated, accurate and data-driven imaging analysis to enable the potential for personalized clinical support.
QyScore®, our FDA-Cleared and CE-Marked AI-powered software platform automatically selects and measures markers of interest that indicate the presence and severity of CNS disease in your patient’s brain scan, such as whole brain, white matter, grey matter by lobe, cerebellum, white matter abnormalities and brain substructures.
This innovative platform adds measurable precision and objectivity to brain scan analysis and provides the potential for improved outcomes for your patient. To facilitate review by physicians, an automated patient report is rapidly generated after each QyScore® analysis and results are viewable in our proprietary and integrated 3D visualization platform.
- Provides the potential for earlier detection
- Produces data and results that may assist in timely diagnosis and
prognosis by comparing results with a large database of controls - Decreases image reading variability and segmentation errors by 89%
- Provides the potential for a more accurate diagnosis, measure of drug
efficacy and the ability to monitor disease progression - Provides MRI analyses that may help inform a healthcare provider’s
ability to monitor safety in patients on therapeutic interventions and
better facilitate therapeutic switching
